Genetics of Lupus in Mice

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 63-105

  Kono, Dwight H ^a   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859412811     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10004-X     Document Type: Chapter

References (420)

1. Bielschowsky M., Helyer B.J., Howie J.B. Spontaneous anemia in mice of the NZB/B1 strain. Proc. Unit. Otago Med. School. 1959, 37.
2. Moser K.L., Kelly J.A., Lessard C.J., Harley J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373-379.
3. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv Immunol 1985, 37:269-390.
4. Theofilopoulos A.N., Kono D.H. Murine lupus models: gene-specific and genome-wide studies. Systemic Lupus Erythematosus 1999, 145-181. Academic Press, San Diego. R.G. Lahita (Ed.).
5. Mountz J.D., Yang P., Wu Q., Zhou J., Tousson A., Fitzgerald A., et al. Genetic segregation of spontaneous erosive arthritis and generalized autoimmune disease in the BXD2 recombinant inbred strain of mice. Scand J Immunol 2005, 61:128-138.
6. Morel L., Mohan C., Yu Y., Croker B.P., Tian N., Deng A., et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997, 158:6019-6028.
7. Mohan C., Morel L., Yang P., Wakeland E.K. Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997, 159:454-465.
8. Mohan C., Alas E., Morel L., Yang P., Wakeland E.K. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998, 101:1362-1372.
9. Mohan C., Yu Y., Morel L., Yang P., Wakeland E.K. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999, 162:6492-6502.
10. Morel L., Blenman K.R., Croker B.P., Wakeland E.K. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 2001, 98:1787-1792.
11. Rozzo S.J., Allard J.D., Choubey D., Vyse T.J., Izui S., Peltz G., et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001, 15:435-443.
12. Wither J.E., Lajoie G., Heinrichs S., Cai Y.C., Chang N., Ciofani A., et al. Functional dissection of lupus susceptibility loci on the New Zealand black mouse chromosome 1: evidence for independent genetic loci affecting T and B cell activation. J Immunol 2003, 171:1697-1706.
13. Laporte C., Ballester B., Mary C., Izui S., Reininger L. The Sgp3 locus on mouse chromosome 13 regulates nephritogenic gp70 autoantigen expression and predisposes to autoimmunity. J Immunol 2003, 171:3872-3877.
14. Kong P.L., Morel L., Croker B.P., Craft J. The centromeric region of chromosome 7 from MRL mice (Lmb3) is an epistatic modifier of Fas for autoimmune disease expression. J Immunol 2004, 172:2785-2794.
15. Wandstrat A.E., Nguyen C., Limaye N., Chan A.Y., Subramanian S., Tian X.H., et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 2004, 21:769-780.
16. Haywood M.E., Rogers N.J., Rose S.J., Boyle J., McDermott A., Rankin J.M., et al. Dissection of BXSB lupus phenotype using mice congenic for chromosome 1 demonstrates that separate intervals direct different aspects of disease. J Immunol 2004, 173:4277-4285.
17. Waters S.T., McDuffie M., Bagavant H., Deshmukh U.S., Gaskin F., Jiang C., et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 2004, 199:255-264.
18. Haraldsson M.K., dela Paz N.G., Kuan J.G., Gilkeson G.S., Theofilopoulos A.N., Kono D.H. Autoimmune alterations induced by the New Zealand Black Lbw2 locus in BWF1 mice. J Immunol 2005, 174:5065-5073.
19. Wither J.E., Loh C., Lajoie G., Heinrichs S., Cai Y.C., Bonventi G., et al. Colocalization of expansion of the splenic marginal zone population with abnormal B cell activation and autoantibody production in B6 mice with an introgressed New Zealand Black chromosome 13 interval. J Immunol 2005, 175:4309-4319.
20. Subramanian S., Yim Y.S., Liu K., Tus K., Zhou X.J., Wakeland E.K. Epistatic suppression of systemic lupus erythematosus: fine mapping of Sles1 to less than 1 mb. J Immunol 2005, 175:1062-1072.
21. Kikuchi S., Fossati-Jimack L., Moll T., Amano H., Amano E., Ida A., et al. Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis. J Immunol 2005, 174:1111-1117.
22. lpr congenic mice reveals significant effects from Lmb3. J Immunol 2007, 178:8195-8202.
23. Liu K., Li Q.Z., Yu Y., Liang C., Subramanian S., Zeng Z., et al. Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis. Genes Immun 2007, 8:634-645.
24. Carlucci F., Cortes-Hernandez J., Fossati-Jimack L., Bygrave A.E., Walport M.J., Vyse T.J., et al. Genetic dissection of spontaneous autoimmunity driven by 129-derived chromosome 1 Loci when expressed on C57BL/6 mice. J Immunol 2007, 178:2352-2360.
25. Loh C., Cai Y.C., Bonventi G., Lajoie G., Macleod R., Wither J.E. Dissociation of the genetic loci leading to b1a and NKT cell expansions from autoantibody production and renal disease in b6 mice with an introgressed new zealand black chromosome 4 interval. J Immunol 2007, 178:1608-1617.
26. Ichii O., Konno A., Sasaki N., Endoh D., Hashimoto Y., Kon Y. Autoimmune glomerulonephritis induced in congenic mouse strain carrying telomeric region of chromosome 1 derived from MRL/MpJ. Histol Histopathol 2008, 23:411-422.
27. Tarasenko T., Kole H.K., Bolland S. A lupus-suppressor BALB/c locus restricts IgG2 autoantibodies without altering intrinsic B cell-tolerance mechanisms. J Immunol 2008, 180:3807-3814.
28. Heidari Y., Fossati-Jimack L., Carlucci F., Walport M.J., Cook H.T., Botto M. A lupus-susceptibility C57BL/6 locus on chromosome 3 (Sle18) contributes to autoantibody production in 129 mice. Genes Immun 2009, 10:47-55.
29. Bygrave A.E., Rose K.L., Cortes-Hernandez J., Warren J., Rigby R.J., Cook H.T., et al. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol. 2004, 2:E243.
30. Gillmore J.D., Hutchinson W.L., Herbert J., Bybee A., Mitchell D.A., Hasserjian R.P., et al. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. Immunology 2004, 112:255-264.
31. Heidari Y., Bygrave A.E., Rigby R.J., Rose K.L., Walport M.J., Cook H.T., et al. Identification of chromosome intervals from 129 and C57BL/6 mouse strains linked to the development of systemic lupus erythematosus. Genes Immun 2006, 7:592-599.
32. Fossati-Jimack L., Cortes-Hernandez J., Norsworthy P.J., Cook H.T., Walport M.J., Botto M. Regulation of B cell tolerance by 129-derived chromosome 1 loci in C57BL/6 mice. Arthritis Rheum 2008, 58:2131-2141.
33. Fujimura T., Hirose S., Jiang Y., Kodera S., Ohmuro H., Zhang D., et al. Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int Immunol 1998, 10:1467-1472.
34. Jacob C.O., Lee S.K., Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3'-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996, 156:3043-3050.
35. Carroll M.C. The role of complement in B cell activation and tolerance. Adv Immunol 2000, 74:61-88.
36. Zhang Y., Schlossman S.F., Edwards R.A., Ou C.N., Gu J., Wu M.X. Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice. Proc Natl Acad Sci USA 2002, 99:878-883.
37. Morel L., Tian X.H., Croker B.P., Wakeland E.K. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 1999, 11:131-139.
38. Mary C., Laporte C., Parzy D., Santiago M.L., Stefani F., Lajaunias F., et al. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000, 165:2987-2996.
39. Miura-Shimura Y., Nakamura K., Ohtsuji M., Tomita H., Jiang Y., Abe M., et al. C1q regulatory region polymorphism down-regulating murine c1q protein levels with linkage to lupus nephritis. J Immunol 2002, 169:1334-1339.
40. c allele. Eur J Immunol 2000, 30:2027-2037.
41. Elliott J.I., McVey J.H., Higgins C.F. The P2X7 receptor is a candidate product of murine and human lupus susceptibility loci: a hypothesis and comparison of murine allelic products. Arthritis Res Ther 2005, 7:R468-475.
42. Jiang Y., Ohtsuji M., Abe M., Li N., Xiu Y., Wen S., et al. Polymorphism and chromosomal mapping of the mouse gene for B-cell activating factor belonging to the tumor necrosis factor family (Baff) and association with the autoimmune phenotype. Immunogenetics 2001, 53:810-813.
43. Rogers N.J., Lees M.J., Gabriel L., Maniati E., Rose S.J., Potter P.K., et al. A defect in Marco expression contributes to systemic lupus erythematosus development via failure to clear apoptotic cells. J Immunol 2009, 182:1982-1990.
44. Vinuesa C.G., Goodnow C.C. Illuminating autoimmune regulators through controlled variation of the mouse genome sequence. Immunity 2004, 20:669-679.
45. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995, 83:301-311.
46. Nishizumi H., Taniuchi I., Yamanashi Y., Kitamura D., Ilic D., Mori S., et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995, 3:549-560.
47. Hibbs M.L., Harder K.W., Armes J., Kountouri N., Quilici C., Casagranda F., et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med 2002, 196:1593-1604.
48. Cornall R.J., Cyster J.G., Hibbs M.L., Dunn A.R., Otipoby K.L., Clark E.A., et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998, 8:497-508.
49. Tedder T.F., Inaoki M., Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997, 6:107-118.
50. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
51. Li D.H., Winslow M.M., Cao T.M., Chen A.H., Davis C.R., Mellins E.D., et al. Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum 2008, 58:3192-3204.
52. Kumanogoh A., Shikina T., Watanabe C., Takegahara N., Suzuki K., Yamamoto M., et al. Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment. Int Immunol 2005, 17:1277-1282.
53. Hermiston M.L., Tan A.L., Gupta V.A., Majeti R., Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 2005, 23:635-647.
54. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
55. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000, 97:3370-3375.
56. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
57. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007, 204:1959-1971.
58. Wang J.H., Avitahl N., Cariappa A., Friedrich C., Ikeda T., Renold A., et al. Aiolos regulates B cell activation and maturation to effector state. Immunity 1998, 9:543-553.
59. Higuchi T., Aiba Y., Nomura T., Matsuda J., Mochida K., Suzuki M., et al. Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 2002, 168:9-12.
60. Qian Y., Qin J., Cui G., Naramura M., Snow E.C., Ware C.F., et al. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity 2004, 21:575-587.
61. Claudio E., Sonder S.U., Saret S., Carvalho G., Ramalingam T.R., Wynn T.A., et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J Immunol 2009, 182:1617-1630.
62. Shimizu T., Mundt C., Licence S., Melchers F., Martensson I.L. VpreB1/VpreB2/lambda 5 triple-deficient mice show impaired B cell development but functional allelic exclusion of the IgH locus. J Immunol 2002, 168:6286-6293.
63. Keenan R.A., De Riva A., Corleis B., Hepburn L., Licence S., Winkler T.H., et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 2008, 321:696-699.
64. Mecklenbrauker I., Saijo K., Zheng N.Y., Leitges M., Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature 2002, 416:860-865.
65. Miyamoto A., Nakayama K., Imaki H., Hirose S., Jiang Y., Abe M., et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 2002, 416:865-869.
66. Yu P., Constien R., Dear N., Katan M., Hanke P., Bunney T.D., et al. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity 2005, 22:451-465.
67. Seth A., Ascione R., Fisher R.J., Mavrothalassitis G.J., Bhat N.K., Papas T.S. The ets gene family. Cell Growth Differ 1992, 3:327-334.
68. Zhang L., Eddy A., Teng Y.T., Fritzler M., Kluppel M., Melet F., et al. An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes. Mol Cell Biol. 1995, 15:6961-6970.
69. Zhang X.K., Gallant S., Molano I., Moussa O.M., Ruiz P., Spyropoulos D.D., et al. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol 2004, 173:6481-6489.
70. Bradshaw S., Zheng W.J., Tsoi L.C., Gilkeson G., Zhang X.K. A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis. Clin Immunol 2008, 129:19-30.
71. Savino M.T., Ortensi B., Ferro M., Ulivieri C., Fanigliulo D., Paccagnini E., et al. Rai acts as a negative regulator of autoimmunity by inhibiting antigen receptor signaling and lymphocyte activation. J Immunol 2009, 182:301-308.
72. Ishida D., Su L., Tamura A., Katayama Y., Kawai Y., Wang S.F., et al. Rap1 signal controls B cell receptor repertoire and generation of self-reactive B1a cells. Immunity 2006, 24:417-427.
73. Wilkinson R., Lyons A.B., Roberts D., Wong M.X., Bartley P.A., Jackson D.E. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease. Blood 2002, 100:184-193.
74. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008.
75. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Trageted disruption of the mouse transforming growth factor-1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
76. Kulkarni A.B., Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993, 143:3-9.
77. Dang H., Geiser A.G., Letterio J.J., Nakabayashi T., Kong L., Fernandes G., et al. SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF- knockout mice. J Immunol 1995, 155:3205-3212.
78. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
79. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
80. Tivol E.A., Boyd S.D., McKeon S., Borriello F., Nickerson P., Strom T.B., et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997, 158:5091-5094.
81. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 1992, 11:3887-3895.
82. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
83. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
84. Nishimura H., Minato N., Nakano T., Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998, 10:1563-1572.
85. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
86. Okazaki T., Tanaka Y., Nishio R., Mitsuiye T., Mizoguchi A., Wang J., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003, 9:1477-1483.
87. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002, 32:666-669.
88. Lin S.C., Yen J.H., Tsai J.J., Tsai W.C., Ou T.T., Liu H.W., et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004, 50:770-775.
89. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 2004, 50:1770-1773.
90. Kong E.K., Prokunina-Olsson L., Wong W.H., Lau C.S., Chan T.M., Alarcon-Riquelme M., et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005, 52:1058-1062.
91. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka K.V., Maurer M., et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005, 58:50-57.
92. Lucas J.A., Menke J., Rabacal W.A., Schoen F.J., Sharpe A.H., Kelley V.R. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol 2008, 181:2513-2521.
93. Menke J., Lucas J.A., Zeller G.C., Keir M.E., Huang X.R., Tsuboi N., et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol 2007, 179:7466-7477.
94. Wang J., Lo J.C., Foster A., Yu P., Chen H.M., Wang Y., et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001, 108:1771-1780.
95. Shaikh R.B., Santee S., Granger S.W., Butrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001, 167:6330-6337.
96. Granger S.W., Ware C.F. Turning on LIGHT. J Clin Invest 2001, 108:1741-1742.
97. Yablonski D., Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv Immunol 2001, 79:93-128.
98. Sommers C.L., Park C.S., Lee J., Feng C., Fuller C.L., Grinberg A., et al. A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 2002, 296:2040-2043.
99. Aguado M.T., Balderas R.S., Rubin R.L., Duchosal M.A., Kofler R., Birshtein B.K., et al. Specificity and molecular characteristics of monoclonal IgM rheumatoid factors from arthritic and non-arthritic mice. J Immunol 1987, 139:1080-1087.
100. Duan L., Reddi A.L., Ghosh A., Dimri M., Band H. The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity 2004, 21:7-17.
101. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000, 403:216-220.
102. Bachmaier K., Krawczyk C., Kozieradzki I., Kong Y.Y., Sasaki T., Oliveira-dos-Santos A., et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000, 403:211-216.
103. Kitaura Y., Jang I.K., Wang Y., Han Y.C., Inazu T., Cadera E.J., et al. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 2007, 26:567-578.
104. Le L.Q., Kabarowski J.H., Weng Z., Satterthwaite A.B., Harvill E.T., Jensen E.R., et al. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 2001, 14:561-571.
105. Vratsanos G.S., Jung S., Park Y.M., Craft J. CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med 2001, 193:329-337.
106. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta 2002, 1602:131-150.
107. Murga M., Fernandez-Capetillo O., Field S.J., Moreno B., Borlado LR., Fujiwara Y., Balomenos D., et al. Mutation of E2F2 in Mice Causes Enhanced T Lymphocyte Proliferation, Leading to the Development of Autoimmunity. Immunity 2001, 15:959-970.
108. Hardy W.R., Li L., Wang Z., Sedy J., Fawcett J., Frank E., et al. Combinatorial ShcA docking interactions support diversity in tissue morphogenesis. Science 2007, 317:251-256.
109. Migliaccio E., Giorgio M., Mele S., Pelicci G., Reboldi P., Pandolfi P.P., et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999, 402:309-313.
110. Finetti F., Pellegrini M., Ulivieri C., Savino M.T., Paccagnini E., Ginanneschi C., et al. The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity. Blood 2008, 111:5017-5027.
111. Yasuda T., Bundo K., Hino A., Honda K., Inoue A., Shirakata M., et al. Dok-1 and Dok-2 are negative regulators of T cell receptor signaling. Int Immunol 2007, 19:487-495.
112. Vinuesa C.G., Cook M.C., Angelucci C., Athanasopoulos V., Rui L., Hill K.M., et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458.
113. Linterman M.A., Rigby R.J., Wong R.K., Yu D., Brink R., Cannons J.L., et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009, 206:561-576.
114. Demetriou M., Granovsky M., Quaggin S., Dennis J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N- glycosylation. Nature 2001, 409:733-739.
115. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739.
116. Vespa G.N., Lewis L.A., Kozak K.R., Moran M., Nguyen J.T., Baum L.G., et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999, 162:799-806.
117. Kim E., Lowenson J.D., MacLaren D.C., Clarke S., Young S.G. Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Proc Natl Acad Sci U S A 1997, 94:6132-6137.
118. Doyle H.A., Gee R.J., Mamula M.J. A failure to repair self-proteins leads to T cell hyperproliferation and autoantibody production. J Immunol 2003, 171:2840-2847.
119. Fan W., Richter G., Cereseto A., Beadling C., Smith K.A. Cytokine response gene 6 induces p21 and regulates both cell growth and arrest. Oncogene 1999, 18:6573-6582.
120. Vairapandi M., Balliet A.G., Fornace A.J., Hoffman B., Liebermann D.A. The differentiation primary response gene MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21WAF1/CIP1. Oncogene 1996, 12:2579-2594.
121. Salvador J.M., Hollander M.C., Nguyen A.T., Kopp J.B., Barisoni L., Moore J.K., et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 2002, 16:499-508.
122. Liu L., Tran E., Zhao Y., Huang Y., Flavell R., Lu B. Gadd45 beta and Gadd45 gamma are critical for regulating autoimmunity. J Exp Med 2005, 202:1341-1347.
123. Becart S., Altman A. SWAP-70-like adapter of T cells: a novel Lck-regulated guanine nucleotide exchange factor coordinating actin cytoskeleton reorganization and Ca2+ signaling in T cells. Immunol Rev. 2009, 232:319-333.
124. Fanzo J.C., Yang W., Jang S.Y., Gupta S., Chen Q., Siddiq A., et al. Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity. J Clin Invest 2006, 116:703-714.
125. Altman A., Becart S. Does Def6 deficiency cause autoimmunity?. Immunity 2009, 31:1-2. author reply 2-3.
126. Balomenos D., Martin-Caballero J., Garcia M.I., Prieto I., Flores J.M., Serrano M., et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000, 6:171-176.
127. Santiago-Raber M.L., Lawson B.R., Dummer W., Barnhouse M., Koundouris S., Wilson C.B., et al. The role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 2001, 167:4067-4074.
128. Lawson B.R., Kono D.H., Theofilopoulos A.N. Deletion of p21 (WAF-1/Cip1) does not induce systemic autoimmunity in female BXSB mice. J Immunol 2002, 168:5928-5932.
129. Bouillet P., Metcalf D., Huang D.C., Tarlinton D.M., Kay T.W., Kontgen F., et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
130. Hutcheson J., Scatizzi J.C., Siddiqui A.M., Haines G.K., Wu T., Li Q.Z., et al. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity 2008, 28:206-217.
131. Strasser A., Whittingham S., Vaux D.L., Bath M.L., Adams J.M., Cory S., et al. Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991, 88:8661-8665.
132. Ray S.K., Putterman C., Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci U S A 1996, 93:2019-2024.
133. Kuo P., Bynoe M., Diamond B. Crossreactive B cells are present during a primary but not secondary response in BALB/c mice expressing a bcl-2 transgene. Mol Immunol 1999, 36:471-479.
134. Mandik-Nayak L., Nayak S., Sokol C., Eaton-Bassiri A., Madaio M.P., Caton A.J., et al. The origin of anti-nuclear antibodies in bcl-2 transgenic mice. Int Immunol 2000, 12:353-364.
135. Schorle H., Holtschke T., Hunig T., Schimpl A., Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352:621-624.
136. Kundig T.M., Schorle H., Bachmann M.F., Hengartner H., Zinkernagel R.M., Horak I. Immune responses in interleukin-2-deficient mice. Science 1993, 262:1059-1061.
137. Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995, 25:3053-3059.
138. Willerford D.M., Chen J., Ferry J.A., Davidson L., Ma A., Alt F.W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3:521-530.
139. Suzuki H., Kundig T.M., Furlonger C., Wakeham A., Timms E., Matsuyama T., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268:1472-1476.
140. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
141. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009, 9:480-490.
142. Marti F., Lapinski P.E., King P.D. The emerging role of the T cell-specific adaptor (TSAd) protein as an autoimmune disease-regulator in mouse and man. Immunol Lett. 2005, 97:165-170.
143. Sundvold-Gjerstad V., Granum S., Mustelin T., Andersen T.C., Berge T., Shapiro M.J., et al. The C terminus of T cell-specific adapter protein (TSAd) is necessary for TSAd-mediated inhibition of Lck activity. Eur J Immunol 2005, 35:1612-1620.
144. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245.
145. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390.
146. Di Cristofano A., Kotsi P., Peng Y.F., Cordon-Cardo C., Elkon K.B., Pandolfi P.P. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999, 285:2122-2125.
147. Browne C.D., Del Nagro C.J., Cato M.H., Dengler H.S., Rickert R.C. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 2009, 31:749-760.
148. Shen L., Zhi L., Hu W., Wu M.X. IEX-1 targets mitochondrial F1Fo-ATPase inhibitor for degradation. Cell Death Differ 2009, 16:603-612.
149. Dower N.A., Stang S.L., Bottorff D.A., Ebinu J.O., Dickie P., Ostergaard H.L., Stone J.C. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol 2000, 1:317-321.
150. Layer K., Lin G., Nencioni A., Hu W., Schmucker A., Antov A.N., et al. Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity 2003, 19:243-255.
151. Sun H., Lu B., Li R.Q., Flavell R.A., Taneja R. Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nat Immunol 2001, 2:1040-1047.
152. Seimiya M., Wada A., Kawamura K., Sakamoto A., Ohkubo Y., Okada S., et al. Impaired lymphocyte development and function in Clast5/Stra13/DEC1-transgenic mice. Eur J Immunol 2004, 34:1322-1332.
153. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998, 19:56-59.
154. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998, 9:721-731.
155. Chen Z., Koralov S.B., Kelsoe G. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med 2000, 192:1339-1352.
156. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet. 2000, 25:177-181.
157. Yasutomo K., Horiuchi T., Kagami S., Tsukamoto H., Hashimura C., Urushihara M., et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001, 28:313-314.
158. Hanayama R., Tanaka M., Miwa K., Shinohara A., Iwamatsu A., Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature 2002, 417:182-187.
159. Akakura S., Singh S., Spataro M., Akakura R., Kim J.I., Albert M.L., et al. The opsonin MFG-E8 is a ligand for the alphavbeta5 integrin and triggers DOCK180-dependent Rac1 activation for the phagocytosis of apoptotic cells. Exp Cell Res. 2004, 292:403-416.
160. Hanayama R., Tanaka M., Miyasaka K., Aozasa K., Koike M., Uchiyama Y., et al. Autoimmune Disease and Impaired Uptake of Apoptotic Cells in MFG-E8-Deficient Mice. Science 2004, 304:1147-1150.
161. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
162. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004, 199:1631-1640.
163. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131-1139.
164. Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005, 202:1171-1177.
165. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575-1585.
166. Savarese E., Chae O.W., Trowitzsch S., Weber G., Kastner B., Akira S., et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006, 107:3229-3234.
167. Lemke G., Rothlin C.V. Immunobiology of the TAM receptors. Nat Rev Immunol 2008, 8:327-336.
168. Lu Q., Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293:306-311.
169. Scott R.S., McMahon E.J., Pop S.M., Reap E.A., Caricchio R., Cohen P.L., et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001, 411:207-211.
170. Cohen P.L., Caricchio R., Abraham V., Camenisch T.D., Jennette J.C., Roubey R.A., et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002, 196:135-140.
171. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
172. Bhoj V.G., Chen Z.J. Linking retroelements to autoimmunity. Cell 2008, 134:569-571.
173. Franceschini F., Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005, 38:55-63.
174. Xue D., Shi H., Smith J.D., Chen X., Noe D.A., Cedervall T., et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A 2003, 100:7503-7508.
175. Espinosa A., Dardalhon V., Brauner S., Ambrosi A., Higgs R., Quintana F.J., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009, 206:1661-1671.
176. Ozato K., Yoshimi R., Chang T.H., Wang H., Atsumi T., Morse H.C. Comment on "Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappa B-dependent cytokine expression in fibroblasts". J Immunol 2009, 183:7619. author reply 7720-7611.
177. Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999, 5:694-697.
178. Mehling A., Loser K., Varga G., Metze D., Luger T.A., Schwarz T., et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 2001, 194:615-628.
179. Seery J.P., Carroll J.M., Cattell V., Watt F.M. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 1997, 186:1451-1459.
180. Fujikado N., Saijo S., Yonezawa T., Shimamori K., Ishii A., Sugai S., et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med 2008, 14:176-180.
181. Erb K.J., Ruger B., von Brevern M., Ryffel B., Schimpl A., Rivett K. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997, 185:329-339.
182. Muller W., Kuhn R., Rajewsky K. Major histocompatibility complex class II hyperexpression on B cells in interleukin 4-transgenic mice does not lead to B cell proliferation and hypergammaglobulinemia. Eur J Immunol 1991, 21:921-925.
183. Burstein H.J., Tepper R.I., Leder P., Abbas A.K. Humoral immune functions in IL-4 transgenic mice. J Immunol 1991, 147:2950-2956.
184. Tepper R.I., Levinson D.A., Stanger B.Z., Campos-Torres J., Abbas A.K., Leder P. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1990, 62:457-467.
185. Lewis D.B., Yu C.C., Forbush K.A., Carpenter J., Sato T.A., Grossman A., et al. Interleukin 4 expressed in situ selectively alters thymocyte development. J Exp Med 1991, 173:89-100.
186. Santiago M., Fossati L., Jacquiet C., Muller W., Izui S., Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997, 185:65-70.
187. Carballo E., Lai W.S., Blackshear P.J. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998, 281:1001-1005.
188. Taylor G.A., Carballo E., Lee D.M., Lai W.S., Thompson M.J., Patel D.D., et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996, 4:445-454.
189. Carballo E., Gilkeson G.S., Blackshear P.J. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. J Clin Invest 1997, 100:986-995.
190. Zhou T., Edwards C.K., Yang P., Wang Z., Bluethmann H., Mountz J.D. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996, 156:2661-2665.
191. Jacob N., Yang H., Pricop L., Liu Y., Gao X., Zheng S.G., et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009, 182:2532-2541.
192. Cassel S.L., Rothman P.B. Chapter 3: Role of SOCS in allergic and innate immune responses. Adv Immunol 2009, 103:49-76.
193. Fujimoto M., Tsutsui H., Xinshou O., Tokumoto M., Watanabe D., Shima Y., et al. Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol 2004, 16:303-314.
194. Thomas M.L. Of ITAMs and ITIMs:turning on and off the B cell antigen receptor. J Exp Med 1995, 181:1953-1956.
195. Shultz L.D., Schweitzer P.A., Rajan T.V., Yi T., Ihle J.N., Matthews R.J., et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993, 73:1445-1454.
196. Tsui H.W., Siminovitch K.A., deSouza L., Tsui F.W.L. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nature Genet. 1993, 4:124-129.
197. v). Experimental hematology 1989, 17:81-87.
198. Scribner C.L., Hansen C.T., Klinman D.M., Steinberg A.D. The interaction of the xid and me genes. J Immunol 1987, 138:3611-3617.
199. Yu C.C., Tsui H.W., Ngan B.Y., Shulman M.J., Wu G.E., Tsui F.W. B and T cells are not required for the viable motheaten phenotype. J Exp Med 1996, 183:371-380.
200. Chui D., Oh-Eda M., Liao Y.F., Panneerselvam K., Lal A., Marek K.W., et al. Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis. Cell 1997, 90:157-167.
201. Moremen K.W., Trimble R.B., Herscovics A. Glycosidases of the asparagine-linked oligosaccharide processing pathway. Glycobiology 1994, 4:113-125.
202. Chui D., Sellakumar G., Green R., Sutton-Smith M., McQuistan T., Marek K., et al. Genetic remodeling of protein glycosylation in vivo induces autoimmune disease. Proc Natl Acad Sci U S A 2001, 98:1142-1147.
203. Hurov J.B., Stappenbeck T.S., Zmasek C.M., White L.S., Ranganath S.H., Russell J.H., et al. Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase. Mol Cell Biol. 2001, 21:3206-3219.
204. Bessone S., Vidal F., Le Bouc Y., Epelbaum J., Bluet-Pajot M.T., Darmon M. EMK protein kinase-null mice: dwarfism and hypofertility associated with alterations in the somatotrope and prolactin pathways. Dev Biol. 1999, 214:87-101.
205. Zipper L.M., Mulcahy R.T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem. 2002, 277:36544-36552.
206. Ishii T., Itoh K., Yamamoto M. Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. Methods Enzymol 2002, 348:182-190.
207. Yoh K., Itoh K., Enomoto A., Hirayama A., Yamaguchi N., Kobayashi M., et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001, 60:1343-1353.
208. Poss K.D., Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci U S A 1997, 94:10919-10924.
209. Morito N., Yoh K., Hirayama A., Itoh K., Nose M., Koyama A., et al. Nrf2 deficiency improves autoimmune nephritis caused by the fas mutation lpr. Kidney Int 2004, 65:1703-1713.
210. Lu X., Kovalev G.I., Chang H., Kallin E., Knudsen G., Xia L., et al. Inactivation of NuRD component Mta2 causes abnormal T cell activation and lupus-like autoimmune disease in mice. J Biol Chem. 2008, 283:13825-13833.
211. Matsushita K., Takeuchi O., Standley D.M., Kumagai Y., Kawagoe T., Miyake T., et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009, 458:1185-1190.
212. Shlomchik M.J., Madaio M.P., Ni D., Trounstein M., Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994, 180:1295-1306.
213. Chan O.T., Madaio M.P., Shlomchik M.J. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol 1999, 163:3592-3596.
214. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1648.
215. Hao Z., Duncan G.S., Seagal J., Su Y.W., Hong C., Haight J., et al. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity 2008, 29:615-627.
216. Jiang C., Foley J., Clayton N., Kissling G., Jokinen M., Herbert R., et al. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J Immunol 2007, 178:7422-7431.
217. Jevnikar A.M., Grusby M.J., Glimcher L.H. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J Exp Med 1994, 179:1137-1143.
218. Koh D.R., Ho A., Rahemtulla A., Fung-Leung W.P., Griesser H., Mak T.W. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 1995, 25:2558-2562.
219. Giese T., Davidson W.F. CD8+ T cell-deficient lpr/lpr mice, CD4+B220+ and CD4+B220- T cells replace B220+ double-negative T cells as the predominant populations in enlarged lymph nodes. J Immunol 1995, 154:4986-4995.
220. Ohteki T., Iwamoto M., Izui S., MacDonald H.R. Reduced development of CD4-8-B220+ T cells but normal autoantibody production in lpr/lpr mice lacking major histocompatibility complex class I molecules. Eur J Immunol 1995, 25:37-41.
221. Maldonado M.A., Eisenberg R.A., Roper E., Cohen P.L., Kotzin B.L. Greatly reduced lymphoproliferation in lpr mice lacking major histocompatibility complex class I. J Exp Med 1995, 181:641-648.
222. Christianson G.J., Blankenburg R.L., Duffy T.M., Panka D., Roths J.B., Marshak-Rothstein A., et al. beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice. J Immunol 1996, 156:4932-4939.
223. Chan O.T., Paliwal V., McNiff J.M., Park S.H., Bendelac A., Shlomchik M.J. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level. J Immunol 2001, 167:2985-2990.
224. Yang J.Q., Chun T., Liu H., Hong S., Bui H., Van Kaer L., et al. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004, 34:1723-1732.
225. Yang J.Q., Singh A.K., Wilson M.T., Satoh M., Stanic A.K., Park J.J., et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003, 171:2142-2153.
226. Yang J.Q., Wen X., Liu H., Folayan G., Dong X., Zhou M., et al. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum 2007, 56:1219-1233.
227. Chen S.Y., Takeoka Y., Ansari A.A., Boyd R., Klinman D.M., Gershwin M.E. The natural history of disease expression in CD4 and CD8 gene-deleted New Zealand black (NZB) mice. J Immunol 1996, 157:2676-2684.
228. Peng S.L., Cappadona J., McNiff J.M., Madaio M.P., Owen M.J., Hayday A.C., et al. Pathogenesis of autoimmunity in alphabeta T cell-deficient lupus-prone mice. Clin Exp Immunol 1998, 111:107-116.
229. Peng S.L., Madaio M.P., Hughes D.P., Crispe I.N., Owen M.J., Wen, Hayday A.C., et al. Murine lupus in the absence of alpha beta T cells. J Immunol 1996, 156:4041-4049.
230. Peng S.L., Craft J. The regulation of murine lupus. Ann N Y Acad Sci. 1997, 815:128-138.
231. Craft J., Peng S., Fujii T., Okada M., Fatenejad S. Autoreactive T cells in murine lupus: origins and roles in autoantibody production. Immunol Res. 1999, 19:245-257.
232. Peng S.L., Moslehi J., Robert M.E., Craft J. Perforin protects against autoimmunity in lupus-prone mice. J Immunol 1998, 160:652-660.
233. Zeller G.C., Hirahashi J., Schwarting A., Sharpe A.H., Kelley V.R. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus. J Am Soc Nephrol 2006, 17:122-130.
234. Tada Y., Koarada S., Tomiyoshi Y., Morito F., Mitamura M., Haruta Y., et al. Role of inducible costimulator in the development of lupus in MRL/lpr mice. Clin Immunol 2006, 120:179-188.
235. Theofilopoulos A.N., Gonzalez-Quintial R., Lawson B.R., Koh Y.T., Stern M.E., Kono D.H., et al. Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol 2010, 6(3):146-156.
236. Nickerson K.M., Christensen S.R., Shupe J., Kashgarian M., Kim D., Elkon K., et al. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010, 184:1840-1848.
237. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of Lupus. Immunity 2006, 25:417-428.
238. Lee P.Y., Kumagai Y., Li Y., Takeuchi O., Yoshida H., Weinstein J., et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008, 205:2995-3006.
239. Kono D.H., Haraldsson M.K., Lawson B.R., Pollard K.M., Koh Y.T., Du X., et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA 2009, 106(29):12061-12066.
240. Sadanaga A., Nakashima H., Akahoshi M., Masutani K., Miyake K., Igawa T., et al. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 2007, 56:1618-1628.
241. Pawar R.D., Ramanjaneyulu A., Kulkarni O.P., Lech M., Segerer S., Anders H.J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007, 18:1721-1731.
242. Marshak-Rothstein A., Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007, 25:419-441.
243. Garlanda C., Anders H.J., Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009, 30:439-446.
244. Lech M., Kulkarni O.P., Pfeiffer S., Savarese E., Krug A., Garlanda C., et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008, 205:1879-1888.
245. Frisoni L., McPhie L., Kang S.A., Monestier M., Madaio M., Satoh M., et al. Lack of chromatin and nuclear fragmentation in vivo impairs the production of lupus anti-nuclear antibodies. J Immunol 2007, 179:7959-7966.
246. Ma J., Xu J., Madaio M.P., Peng Q., Zhang J., Grewal I.S., et al. Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 1996, 157:417-426.
247. Peng S.L., McNiff J.M., Madaio M.P., Ma J., Owen M.J., Flavell Ra., et al. alpha-beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol 1997, 158:2464-2470.
248. Tada Y., Nagasawa K., Ho A., Morito F., Koarada S., Ushiyama O., et al. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J Immunol 1999, 163:3153-3159.
249. Liang B., Gee R.J., Kashgarian M.J., Sharpe A.H., Mamula M.J. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-B7.1/B7.2 blocking antibodies. J Immunol 1999, 163:2322-2329.
250. Nakajima A., Azuma M., Kodera S., Nuriya S., Terashi A., Abe M., et al. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol 1995, 25:3060-3069.
251. Detre C., Keszei M., Romero X., Tsokos G.C., Terhorst C. SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Semin Immunopathol 2010, 32(2):157-171.
252. Hron J.D., Caplan L., Gerth A.J., Schwartzberg P.L., Peng S.L. SH2D1A regulates T-dependent humoral autoimmunity. J Exp Med 2004, 200:261-266.
253. Komori H., Furukawa H., Mori S., Ito M.R., Terada M., Zhang M.C., et al. A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice. J Immunol 2006, 176:395-400.
254. Kevil C.G., Hicks M.J., He X., Zhang J., Ballantyne C.M., Raman C., et al. Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. Am J Pathol 2004, 165:609-616.
255. Santiago-Raber M., Baccala R., Haraldsson M.K., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788.
256. Braun D., Geraldes P., Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003, 20:15-25.
257. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007, 56:3770-3783.
258. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005, 174:2499-2506.
259. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I Interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-335.
260. Hron J.D., Peng S.L. Type I IFN protects against murine lupus. J Immunol 2004, 173:2134-2142.
261. Schwarting A., Paul K., Tschirner S., Menke J., Hansen T., Brenner W., et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005, 16:3264-3272.
262. Peng S.L., Moslehi J., Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997, 99:1936-1946.
263. Haas C., Ryffel B., Le H.M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol 1997, 158:5484-5491.
264. Balomenos D., Rumold R., Theofilopoulos A.N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998, 101:364-371.
265. Haas C., Ryffel B., Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 1998, 160:3713-3718.
266. Kono D.H., Balomenos D., Pearson D.L., Park M.S., Hildebrandt B., Hultman P., et al. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN- gamma and not Th1/Th2 imbalance. J Immunol 1998, 161:234-240.
267. Ho I.C., Glimcher L.H. Transcription: tantalizing times for T cells. Cell. 2002, 109 Suppl:S109-120.
268. Peng S.L., Szabo S.J., Glimcher L.H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A 2002, 99:5545-5550.
269. Shimohata H., Yamada A., Yoh K., Ishizaki K., Morito N., Yamagata K., et al. Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background. J Nephrol 2009, 22:123-129.
270. Reilly C.M., Olgun S., Goodwin D., Gogal R.M., Santo A., Romesburg J.W., et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol 2006, 36:1296-1308.
271. Robinson D.S., O'Garra A. Further checkpoints in Th1 development. Immunity 2002, 16:755-758.
272. Yasuda T., Yoshimoto T., Tsubura A., Matsuzawa A. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice. Cell Immunol 2001, 210:77-86.
273. Kono D.H., Balomenos D., Park M.S., Theofilopoulos A.N. Development of lupus in BXSB mice is independent of IL-4. J Immunol 2000, 164:38-42.
274. Xu Z., Duan B., Croker B.P., Morel L. STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus. Clin Immunol 2006, 120:189-198.
275. Singh R.R., Saxena V., Zang S., Li L., Finkelman F.D., Witte D.P., et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003, 170:4818-4825.
276. Thibault D.L., Chu A.D., Graham K.L., Balboni I., Lee L.Y., Kohlmoos C., et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 2008, 118:1417-1426.
277. Yin Z., Bahtiyar G., Zhang N., Liu L., Zhu P., Robert M.E., et al. IL-10 regulates murine lupus. J Immunol 2002, 169:2148-2155.
278. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864.
279. Weber G.F., Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clin Exp Immunol 2001, 126:578-583.
280. Patarca R., Wei F.Y., Singh P., Morasso M.I., Cantor H. Dysregulated expression of the T cell cytokine Eta-1 in CD4-8- lymphocytes during the development of murine autoimmune disease. J Exp Med 1990, 172:1177-1183.
281. Igawa T., Nakashima H., Sadanaga A., Masutani K., Miyake K., Shimizu S., et al. Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis. Mod Rheumatol 2009, 19:33-41.
282. Bubier J.A., Sproule T.J., Foreman O., Spolski R., Shaffer D.J., Morse H.C., et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A 2009, 106:1518-1523.
283. Balomenos D., Rumold R., Theofilopoulos A.N. The proliferative in vivo activities of lpr double-negative T cells and the primary role of p59fyn in their activation and expansion. J Immunol 1997, 159:2265-2273.
284. Brooks W.P., Lynes M.A. Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol 2001, 212:24-34.
285. Watanabe H., Garnier G., Circolo A., Wetsel R.A., Ruiz P., Holers V.M., et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 2000, 164:786-794.
286. Passwell J., Schreiner G.F., Nonaka M., Beuscher H.U., Colten H.R. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 1988, 82:1676-1684.
287. Elliott M.K., Jarmi T., Ruiz P., Xu Y., Holers V.M., Gilkeson G.S. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int 2004, 65:129-138.
288. Sekine H., Reilly C.M., Molano I.D., Garnier G., Circolo A., Ruiz P., et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001, 166:6444-6451.
289. Einav S., Pozdnyakova O.O., Ma M., Carroll M.C. Complement C4 is protective for lupus disease independent of C3. J Immunol 2002, 168:1036-1041.
290. Bao L., Haas M., Boackle S.A., Kraus D.M., Cunningham P.N., Park P., et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002, 168:3601-3607.
291. Miwa T., Maldonado M.A., Zhou L., Sun X., Luo H.Y., Cai D., et al. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 2002, 161:1077-1086.
292. Miwa T., Maldonado M.A., Zhou L., Yamada K., Gilkeson G.S., Eisenberg R.A., et al. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol 2007, 170:1258-1266.
293. Svenson J.L., EuDaly J., Ruiz P., Korach K.S., Gilkeson G.S. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol 2008, 128:259-268.
294. Bynote K.K., Hackenberg J.M., Korach K.S., Lubahn D.B., Lane P.H., Gould K.A. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun 2008, 9:137-152.
295. Lloyd C.M., Gonzalo J.A., Salant D.J., Just J., Gutierrez-Ramos J.C. Intercellular adhesion molecule-1 deficiency prolongs survival and protects against the development of pulmonary inflammation during murine lupus. J Clin Invest 1997, 100:963-971.
296. Bullard D.C., King P.D., Hicks M.J., Dupont B., Beaudet A.L., Elkon K.B. Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas(lpr) mice from early lethality. J Immunol 1997, 159:2058-2067.
297. Norman M.U., James W.G., Hickey M.J. Differential roles of ICAM-1 and VCAM-1 in leukocyte-endothelial cell interactions in skin and brain of MRL/faslpr mice. J Leukoc Biol. 2008, 84:68-76.
298. Gilkeson G.S., Mudgett J.S., Seldin M.F., Ruiz P., Alexander A.A., Misukonis M.A., et al. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med 1997, 186:365-373.
299. Clynes R., Dumitru C., Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
300. Park S.Y., Ueda S., Ohno H., Hamano Y., Tanaka M., Shiratori T., et al. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J Clin Invest 1998, 102:1229-1238.
301. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte Chemoattractant Protein 1-dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in MRL-Fas(lpr) Mice. J Exp Med 1999, 190:1813-1824.
302. Hoi A.Y., Hickey M.J., Hall P., Yamana J., O'Sullivan K.M., Santos L.L., et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006, 177:5687-5696.
303. Liu K., Li Q.Z., Delgado-Vega A.M., Abelson A.K., Sanchez E., Kelly J.A., et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest 2009, 119:911-923.
304. Yoshida M., Saiga K., Hato T., Iwaki S., Niiya T., Arita N., et al. Cappuccino mutation in an autoimmune-prone strain of mice suggests a role of platelet function in the progression of immune complex crescentic glomerulonephritis. Arthritis Rheum 2006, 54:2934-2943.
305. He X., Schoeb T.R., Panoskaltsis-Mortari A., Zinn K.R., Kesterson R.A., Zhang J., et al. Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J Immunol 2006, 177:8748-8756.
306. Crowley S.D., Vasievich M.P., Ruiz P., Gould S.K., Parsons K.K., Pazmino A.K., et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119:943-953.
307. Komori T., Pricop L., Hatakeyama A., Bona C.A., Alt F.W. Repertoires of antigen receptors in Tdt congenitally deficient mice. Int Rev Immunol 1996, 13:317-325.
308. Weller S., Conde C., Knapp A.M., Levallois H., Gilfillan S., Pasquali J.L., et al. Autoantibodies in mice lacking terminal deoxynucleotidyl transferase: evidence for a role of N region addition in the polyreactivity and in the affinities of anti-DNA antibodies. J Immunol 1997, 159:3890-3898.
309. Molano I.D., Wloch M.K., Alexander A.A., Watanabe H., Gilkeson G.S. Effect of a genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production by C57BL6 fas(lpr) mice. Clin Immunol 2000, 94:24-32.
310. lpr mice. J Immunol 2001, 167:3486-3493.
311. Ma Z., Choudhury A., Kang S.A., Monestier M., Cohen P.L., Eisenberg R.A. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 2008, 127:168-175.
312. Feng X., Li H., Rumbin A.A., Wang X., La Cava A., Brechtelsbauer K., et al. ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. Journal of lipid research 2007, 48:794-805.
313. Allende C.C., Allende J.E. Promiscuous subunit interactions: a possible mechanism for the regulation of protein kinase CK2. J Cell Biochem Suppl. 1998, 31:129-136.
314. Xu X., Landesman-Bollag E., Channavajhala P.L., Seldin D.C. Murine protein kinase CK2: gene and oncogene. Mol Cell Biochem 1999, 191:65-74.
315. Spurney R.F., Ruiz P., Pisetsky D.S., Coffman T.M. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites. Kidney Int 1991, 39:95-102.
316. Rudofsky U.H., Evans B.D., Balaban S.L., Mottironi V.D., Gabrielsen A.E. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest 1993, 68:419-426.
317. Fossati L., Takahashi S., Merino R., Iwamoto M., Aubry J.P., Nose M., et al. An MRL/MpJ-lpr/lpr substrain with a limited expansion of lpr double-negative T cells and a reduced autoimmune syndrome. Int Immunol 1993, 5:525-532.
318. Suzuka H., Yoshifusa H., Nakamura Y., Miyawaki S., Shibata Y. Morphological analysis of autoimmune disease in MRL-lpr, Yaa male mice with rapidly progressive systemic lupus erythematosus. Autoimmunity 1993, 14:275-282.
319. Kinjoh K., Kyogoku M., Good R.A. Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 1993, 90:3413-3417.
320. Kofler R., McConahey P.J., Duchosal M.A., Balderas R.S., Theofilopoulos A.N., Dixon F.J. An autosomal recessive gene that delays expression of lupus in BXSB mice. J Immunol 1991, 146:1375-1379.
321. Haywood M.E., Gabriel L., Rose S.J., Rogers N.J., Izui S., Morley B.J. BXSB/long-lived is a recombinant inbred strain containing powerful disease suppressor loci. J Immunol 2007, 179:2428-2434.
322. Vidal S., Gelpi C., Rodriguez-Sanchez J.L. (SWR x SJL)F1 mice: a new model of lupus-like disease. J Exp Med 1994, 179:1429-1435.
323. Walker S.E., Gray R.H., Fulton M., Wigley R.D., Schnitzer B. Palmerston North mice, a new animal model of systemic lupus erythematosus. J Lab Clin Med 1978, 92:932-945.
324. Bignon J.S., Siminovitch K.A. Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten mice: a step toward defining the roles of protein tyrosine phosphatases in the regulation of hemopoietic cell differentiation and function. Clin Immunol Immunopathol 1994, 73:168-179.
325. Pollard K.M., Hultman P. Effects of mercury on the immune system. Met Ions Biol Syst 1997, 34:421-440.
326. Rubin R.L. Drug-induced lupus. Dubois' Lupus Erythematosus 1997, 871-901. Williams and Wilkens, Baltimore. D.J. Wallace, B.H. Hahn (Eds.).
327. Satoh M., Kumar A., Kanwar Y.S., Reeves W.H. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA 1995, 92:10934-10938.
328. Mendlovic S., Fricke B.H., Shoenfeld Y., Bakimer R., Mozes E. The genetic regulation of the induction of experimental SLE. Immunol 1990, 69:228-236.
329. Silveira P.A., Baxter A.G. The NOD mouse as a model of SLE. Autoimmunity 2001, 34:53-64.
330. Jordan M.A., Silveira P.A., Shepherd D.P., Chu C., Kinder S.J., Chen J., et al. Linkage analysis of systemic lupus erythematosus induced in diabetes- prone nonobese diabetic mice by Mycobacterium bovis. J Immunol 2000, 165:1673-1684.
331. Schoenecker J.G., Johnson R.K., Lesher A.P., Day J.D., Love S.D., Hoffman M.R., et al. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001, 159:1957-1969.
332. Haywood M.E., Hogarth M.B., Slingsby J.H., Rose S.J., Allen P.J., Thompson E.M., et al. Identification of intervals on chromosomes 1, 3, and 13 linked to the development of lupus in BXSB mice. Arthritis Rheum 2000, 43:349-355.
333. Hogarth M.B., Slingsby J.H., Allen P.J., Thompson E.M., Chandler P., Davies K.A., et al. Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J Immunol 1998, 161:2753-2761.
334. Vyse T.J., Morel L., Tanner F.J., Wakeland E.K., Kotzin B.L. Backcross analysis of genes linked to autoantibody production in New Zealand White mice. J Immunol 1996, 157:2719-2727.
335. Nishihara M., Terada M., Kamogawa J., Ohashi Y., Mori S., Nakatsuru S., et al. Genetic basis of autoimmune sialadenitis in MRL/lpr lupus-prone mice: additive and hierarchical properties of polygenic inheritance. Arthritis Rheum 1999, 42:2616-2623.
336. Xie S., Chang S., Yang P., Jacob C., Kaliyaperumal A., Datta S.K., et al. Genetic contributions of nonautoimmune SWR mice toward lupus nephritis. J Immunol 2001, 167:7141-7149.
337. Morel L., Rudofsky U.H., Longmate J.A., Schiffenbauer J., Wakeland E.K. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994, 1:219-229.
338. Morel L., Mohan C., Yu Y., Schiffenbauer J., Rudofsky U.H., Tian N., et al. Multiplex inheritance of component phenotypes in a murine model of lupus. Mamm Genome 1999, 10:176-181.
339. Kono D.H., Park M.S., Szydlik A., Haraldsson K.M., Kuan J.D., Pearson D.L., et al. Resistance to xenobiotic-induced autoimmunity maps to chromosome 1. J Immunol 2001, 167:2396-2403.
340. Waters S.T., Fu S.M., Gaskin F., Deshmukh U.S., Sung S.S., Kannapell C.C., et al. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol 2001, 100:372-383.
341. Kono D.H., Burlingame R.W., Owens D.G., Kuramochi A., Balderas R.S., Balomenos D., et al. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 1994, 91:10168-10172.
342. Drake C.G., Rozzo S.J., Hirschfeld H.F., Smarnworawong N.P., Palmer E., Kotzin B.L. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. J Immunol 1995, 154:2441-2447.
343. Vyse T.J., Rozzo S.J., Drake C.G., Izui S., Kotzin B.L. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J Immunol 1997, 158:5566-5574.
344. Rozzo S.J., Vyse T.J., Drake C.G., Kotzin B.L. Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. Proc Natl Acad Sci USA 1996, 93:15164-15168.
345. Xie S., Li L., Chang S., Sharma R., Kaliyaperumal A., Datta S.K., et al. Genetic origin of lupus in NZB/SWR hybrids: lessons from an intercross study. Arthritis Rheum 2005, 52:659-667.
346. Gu L., Weinreb A., Wang X.P., Zack D.J., Qiao J.H., Weisbart R., et al. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus. J Immunol 1998, 161:6999-7006.
347. Rahman Z.S., Tin S.K., Buenaventura P.N., Ho C.H., Yap E.P., Yong R.Y., et al. A novel susceptibility locus on chromosome 2 in the (New Zealand Black x New Zealand White)F1 hybrid mouse model of systemic lupus erythematosus. J Immunol 2002, 168:3042-3049.
348. Wang Y., Nose M., Kamoto T., Nishimura M., Hiai H. Host modifier genes affect mouse autoimmunity induced by the lpr gene. Am J Pathol 1997, 151:1791-1798.
349. Rigby R.J., Rozzo S.J., Boyle J.J., Lewis M., Kotzin B.L., Vyse T.J. New loci from New Zealand Black and New Zealand White mice on chromosomes 4 and 12 contribute to lupus-like disease in the context of BALB/c. J Immunol 2004, 172:4609-4617.
350. Miyazaki T., Ono M., Qu W.M., Zhang M.C., Mori S., Nakatsuru S., et al. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur J Immunol 2005, 35:1510-1520.
351. Ida A., Hirose S., Hamano Y., Kodera S., Jiang Y., Abe M., et al. Multigenic control of lupus-associated antiphospholipid syndrome in a model of (NZW x BXSB) F1 mice. Eur J Immunol 1998, 28:2694-2703.
352. Ochiai K., Ozaki S., Tanino A., Watanabe S., Ueno T., Mitsui K., et al. Genetic regulation of anti-erythrocyte autoantibodies and splenomegaly in autoimmune hemolytic anemia-prone new zealand black mice. Int Immunol 2000, 12:1-8.
353. lpr mice. J Clin Invest 1998, 101:696-702.
354. Drake C.G., Babcock S.K., Palmer E., Kotzin B.L. Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW)F1 mice. Proc Natl Acad Sci USA 1994, 91:4062-4066.
355. Hirose S., Tsurui H., Nishimura H., Jiang Y., Shirai T. Mapping of a gene for hypergammaglobulinemia to the distal region on chromosome 4 in NZB mice and its contribution to systemic lupus erythematosus in (NZB x NZW)F1 mice. Int Immunol 1994, 6:1857-1864.
356. Jiang Y., Hirose S., Hamano Y., Kodera S., Tsurui H., Abe M., et al. Mapping of a gene for the increased susceptibility of B1 cells to Mott cell formation in murine autoimmune disease. J Immunol 1997, 158:992-997.
357. Nakatsuru S., Terada M., Nishihara M., Kamogawa J., Miyazaki T., Qu W.M., et al. Genetic dissection of the complex pathological manifestations of collagen disease in MRL/lpr mice. Pathology international 1999, 49:974-982.
358. Watson M.L., Rao J.K., Gilkeson G.S., Ruiz P., Eicher E.M., Pisetsky D.S., et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992, 176:1645-1656.
359. Vyse T.J., Drake C.G., Rozzo S.J., Roper E., Izui S., Kotzin B.L. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J Clin Invest 1996, 98:1762-1772.
360. Bolland S., Yim Y.S., Tus K., Wakeland E.K., Ravetch J.V. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 2002, 195:1167-1174.
361. Haywood M.E., Vyse T.J., McDermott A., Thompson E.M., Ida A., Walport M.J., et al. Autoantigen glycoprotein 70 expression is regulated by a single locus, which acts as a checkpoint for pathogenic anti-glycoprotein 70 autoantibody production and hence for the corresponding development of severe nephritis, in lupus-prone PXSB mice. J Immunol 2001, 167:1728-1733.
362. Rozzo S.J., Vyse T.J., Menze K., Izui S., Kotzin B.L. Enhanced susceptibility to lupus contributed from the nonautoimmune C57BL/10, but not C57BL/6, genome. J Immunol 2000, 164:5515-5521.
363. Fujii T., Iida Y., Yomogida M., Ikeda K., Haga T., Jikumaru Y., et al. Genetic control of the spontaneous activation of CD4(+) Th cells in systemic lupus erythematosus-prone (NZB x NZW) F(1) mice. Genes Immun 2006, 7:647-654.
364. Santiago M.L., Mary C., Parzy D., Jacquet C., Montagutelli X., Parkhouse R.M., et al. Linkage of a major quantitative trait locus to Yaa gene-induced lupus- like nephritis in (NZW x C57BL/6)F1 mice. Eur J Immunol 1998, 28:4257-4267.
365. Kamogawa J., Terada M., Mizuki S., Nishihara M., Yamamoto H., Mori S., et al. Arthritis in MRL/lpr mice is under the control of multiple gene loci with an allelic combination derived from the original inbred strains. Arthritis Rheum 2002, 46:1067-1074.
366. Tucker R.M., Vyse T.J., Rozzo S., Roark C.L., Izui S., Kotzin B.L. Genetic control of glycoprotein 70 autoantigen production and its influence on immune complex levels and nephritis in murine lupus. J Immunol 2000, 165:1665-1672.
367. Choubey D., Duan X., Dickerson E., Ponomareva L., Panchanathan R., Shen H., et al. Interferon-Inducible p200-Family Proteins as Novel Sensors of Cytoplasmic DNA: Role in Inflammation and Autoimmunity. J Interferon Cytokine Res 2010, 30(6):371-380.
368. Cheung Y.H., Chang N.H., Cai Y.C., Bonventi G., MacLeod R., Wither J.E. Functional interplay between intrinsic B and T cell defects leads to amplification of autoimmune disease in New Zealand black chromosome 1 congenic mice. J Immunol 2005, 175:8154-8164.
369. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
370. Kumar K.R., Li L., Yan M., Bhaskarabhatla M., Mobley A.B., Nguyen C., et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 2006, 312:1665-1669.
371. Rahman Z.S., Manser T. Failed up-regulation of the inhibitory IgG Fc receptor Fc gamma RIIB on germinal center B cells in autoimmune-prone mice is not associated with deletion polymorphisms in the promoter region of the Fc gamma RIIB gene. J Immunol 2005, 175:1440-1449.
372. Jiang Y., Hirose S., Sanokawa-Akakura R., Abe M., Mi X., Li N., et al. Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int Immunol 1999, 11:1685-1691.
373. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., et al. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001, 15:775-785.
374. Haraldsson M.K., Louis-Dit-Sully C.A., Lawson B.R., Sternik G., Santiago-Raber M.L., Gascoigne N.R., et al. The lupus-related Lmb3 locus contains a disease-suppressing Coronin-1A gene mutation. Immunity 2008, 28:40-51.
375. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
376. Subramanian S., Tus K., Li Q.Z., Wang A., Tian X.H., Zhou J., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 2006, 103:9970-9975.
377. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication. Science 2006, 312:1669-1672.
378. Majeti R., Xu Z., Parslow T.G., Olson J.L., Daikh D.I., Killeen N., et al. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 2000, 103:1059-1070.
379. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
380. Yajima K., Nakamura A., Sugahara A., Takai T. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Eur J Immunol 2003, 33:1020-1029.
381. Drappa J., Kamen L.A., Chan E., Georgiev M., Ashany D., Marti F., et al. Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. J Exp Med 2003, 198:809-821.
382. Walport M.J., Davies K.A., Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998, 199:265-285.
383. Mitchell D.A., Pickering M.C., Warren J., Fossati-Jimack L., Cortes-Hernandez J., Cook H.T., et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002, 168:2538-2543.
384. Lai W.S., Carballo E., Strum J.R., Kennington E.A., Phillips R.S., Blackshear P.J. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 1999, 19:4311-4323.
385. O'Keefe T.L., Williams G.T., Davies S.L., Neuberger M.S. Hyperresponsive B cells in CD22-deficient mice. Science 1996, 274:798-801.
386. O'Keefe T.L., Williams G.T., Batista F.D., Neuberger M.S. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999, 189:1307-1313.
387. Yu C.C., Yen T.S., Lowell C.A., DeFranco A.L. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr Biol 2001, 11:34-38.
388. Qian Y., Liu C., Hartupee J., Altuntas C.Z., Gulen M.F., Jane-Wit D., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8:247-256.
389. Qian Y., Giltiay N., Xiao J., Wang Y., Tian J., Han S., et al. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. Eur J Immunol 2008, 38:2219-2228.
390. Seshasayee D., Valdez P., Yan M., Dixit V.M., Tumas D., Grewal I.S. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003, 18:279-288.
391. Kikuchi S., Pastore Y., Fossati-Jimack L., Kuroki A., Yoshida H., Fulpius T., et al. A transgenic mouse model of autoimmune glomerulonephritis and necrotizing arteritis associated with cryoglobulinemia. J Immunol 2002, 169:4644-4650.
392. Matsumoto K., Watanabe N., Akikusa B., Kurasawa K., Matsumura R., Saito Y., et al. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum 2003, 48:486-494.
393. Wu X., Jiang N., Deppong C., Singh J., Dolecki G., Mao D., et al. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J Immunol 2002, 169:1587-1592.
394. Chen S.Y., Takeoka Y., Pike-Nobile L., Ansari A.A., Boyd R., Gershwin M.E. Autoantibody production and cytokine profiles of MHC class I (beta2- microglobulin) gene deleted New Zealand black (NZB) mice. Clin Immunol Immunopathol 1997, 84:318-327.
395. Goulet J.L., Griffiths R.C., Ruiz P., Spurney R.F., Pisetsky D.S., Koller B.H., et al. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J Immunol 1999, 163:359-366.
396. Chesnutt M.S., Finck B.K., Killeen N., Connolly M.K., Goodman H., Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4- deficient MRL/lpr mice. Clin Immunol Immunopathol 1998, 87:23-32.
397. Sun J., Matthias G., Mihatsch M.J., Georgopoulos K., Matthias P. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J Immunol 2003, 170:1699-1706.
398. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202:321-331.
399. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196-200.
400. Schwarting A., Wada T., Kinoshita K., Tesch G., Kelley V.R. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL- Fas(lpr) mice. J Immunol 1998, 161:494-503.
401. Takahashi T., Yagi T., Kakinuma S., Kurokawa A., Okada T., Takatsu K., et al. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn). J Immunol 1997, 159:2532-2541.
402. Cattell V. Nitric oxide and glomerulonephritis. Semin Nephrol 1999, 19:277-287.
403. Peng S.L., Craft J. T cells in murine lupus: propagation and regulation of disease. Mol Biol Rep 1996, 23:247-251.
404. Peng S.L., Madaio M.P., Hayday A.C., Craft J. Propagation and regulation of systemic autoimmunity by gammadelta T cells. J Immunol 1996, 157:5689-5698.
405. Wen L., Pao W., Wong F.S., Peng Q., Craft J., Zheng B., et al. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells. J Exp Med 1996, 183:2271-2282.
406. Lawson B.R., Koundouris S.I., Barnhouse M., Dummer W., Baccala R., Kono D.H., et al. The role of alpha beta+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus. J Immunol 2001, 167:2354-2360.
407. lpr mice. J Immunol 2000, 164:6046-6056.
408. Paisansinsup T., Vallejo A.N., Luthra H., David C.S. HLA-DR modulates autoantibody repertoire, but not mortality, in a humanized mouse model of systemic lupus erythematosus. J Immunol 2001, 167:4083-4090.
409. Kontoyiannis D., Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000, 30:2038-2047.
410. Conde C., Weller S., Gilfillan S., Marcellin L., Martin T., Pasquali J.L. Terminal deoxynucleotidyl transferase deficiency reduces the incidence of autoimmune nephritis in (New Zealand Black x New Zealand White)F1 mice. J Immunol 1998, 161:7023-7030.
411. Santiago-Raber M.L., Kikuchi S., Borel P., Uematsu S., Akira S., Kotzin B.L., et al. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol 2008, 181:1556-1562.
412. Rifkin I.R., Channavajhala P.L., Kiefer H.L., Carmack A.J., Landesman-Bollag E., Beaudette B.C., et al. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha. J Immunol 1998, 161:5164-5170.
413. Sanz I., Lee F.E. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337.
414. Vinuesa C.G., Rigby R.J., Yu D. Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol 2009, 28:112-138.
415. Yu D., Tan H.A., Hu X., Athanasopoulos V., Simpson N., Silva D.G., et al. Roquin suppresses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007, 450:299-303.
416. Simpson N., Gatenby P.A., Wilson A., Malik S., Fulcher D.A., Tangye S.G., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 62:234-344.
417. Pao L.I., Lam K.P., Henderson J.M., Kutok J.L., Alimzhanov M., Nitschke L., et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007, 27:35-48.
418. Nagata S., Nagase H., Kawane K., Mukae N., Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ 2003, 10:108-116.
419. Webb R., Merrill J.T., Kelly J.A., Sestak A., Kaufman K.M., Langefeld C.D., et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009, 60:2402-2407.
420. Kyttaris V.C., Zhang Z., Kuchroo V.K., Oukka M., Tsokos G.C. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 2010, 184:4605-4609.